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Abstract 
Several recent articles have called for the regulation of consumer transcranial direct current stimulation 
(tDCS) devices, which provide low levels of electrical current to the brain. However, most of the discussion 
to-date has focused on ethical or normative considerations; there has been a notable absence of 
scholarship regarding the actual legal framework in the United States. This article aims to fill that gap by 
providing a pragmatic analysis of the consumer tDCS market and relevant laws and regulations. In the five 
main sections of this manuscript, I take into account (a) the history of the do-it-yourself tDCS movement 
and the subsequent emergence of direct-to-consumer devices; (b) the statutory language of the Federal 
Food, Drug and Cosmetic Act and how the definition of a medical device—which focuses on the intended 
use of the device rather than its mechanism of action—is of paramount importance for discussions of 
consumer tDCS device regulation; (c) how both the Food and Drug Administration (FDA) and courts have 
understood the FDA's jurisdiction over medical devices in cases where the meaning of ‘intended use’ has 
been challenged; (d) an analysis of consumer tDCS regulatory enforcement action to-date; and (e) the 
multiple US authorities, other than the FDA, that can regulate consumer brain stimulation devices. Taken 
together, this paper demonstrates that rather than a ‘regulatory gap,’ there are multiple, distinct pathways 
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ABSTRACT
Several recent articles have called for the regulation of consumer tran-
scranial direct current stimulation (tDCS) devices, which provide low lev-
els of electrical current to the brain.However,most of the discussion to-date
has focusedonethical or normative considerations; there has been anotable
absence of scholarship regarding the actual legal framework in the United
States. This article aims to fill that gap by providing a pragmatic analysis of
the consumer tDCS market and relevant laws and regulations. In the five
main sections of this manuscript, I take into account (a) the history of the
do-it-yourself tDCSmovement and the subsequent emergence of direct-to-
consumerdevices; (b) the statutory languageof theFederal Food,Drug and
Cosmetic Act and how the definition of a medical device—which focuses
on the intended use of the device rather than its mechanism of action—is
of paramount importance for discussions of consumer tDCS device regu-
lation; (c) how both the Food and Drug Administration (FDA) and courts
have understood the FDA’s jurisdiction overmedical devices in caseswhere
the meaning of ‘intended use’ has been challenged; (d) an analysis of con-
sumer tDCS regulatory enforcement action to-date; and (e) the multi-
ple US authorities, other than the FDA, that can regulate consumer brain
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stimulation devices. Taken together, this paper demonstrates that rather
than a ‘regulatory gap,’ there are multiple, distinct pathways by which con-
sumer tDCS can be regulated in the United States.
KEYWORDS: food and drug law, human enhancement, medical devices,
neuroscience, regulation, transcranial direct current stimulation (tDCS)
INTRODUCTION
Transcranial direct current stimulation (tDCS) is a non-invasive form of brain stimu-
lation that is thought to provide a constant low level of electrical current to the brain.
Approximately 1000 scientific studies have been published in peer-reviewed journals
in the last decade,1 many of which suggest the beneficial effects of tDCS in both clin-
ical populations, for treating a variety of conditions and psychiatric disorders, and in
healthy individuals, for enhancing everything from creative problem solving to the
acquisitionofmotor skills.2 Because a tDCSdevice is relatively easy tomake (and cheap
to acquire), there has arisen amovementwherein individuals stimulate their ownbrains
with tDCS outside of research or medical settings for self-improvement purposes.The
movement has been colloquially referred to as do-it-yourself (DIY) tDCS as it began
with individuals constructing tDCS devices themselves. Since today many individuals
who identify with the DIY tDCSmovement purchase ready-made, direct-to-consumer
(DTC) devices,3 the border between DIY and DTC has become muddled. In this pa-
per, I refer to those who use tDCS devices outside of professional research andmedical
settings as ‘homeusers’.Thus, there currently exists twogroups—researchers andhome
users—who utilize a single technology (sometimes even the exact same device) in very
differentways.Whereas researchers apply tDCS to subjectswithin the controlled realm
of the laboratory, home users apply tDCS on themselves, mostly in private settings, for
cognitive enhancement or self-treatment.
Unsurprisingly, the use of tDCS outside of research settings has not been well re-
ceived by scientists, many of whom believe that home users may ‘ruin it’ for the entire
1 Pubmed title search for ‘transcranial direct current stimulation’ or ‘tDCS’, http://www.ncbi.nlm.nih.gov/
pubmed/?term=(%22transcranial+direct+current+stimulation%22%5BTitle%5D)+OR+tdcs%5BTitle
%5D
2 For a review of clinical tDCS studies, see Min-Fang Kuo, Walter Paulus & Michael A. Nitsche, Thera-
peutic Effects of Non-Invasive Brain Stimulation with Direct Currents (tDCS) in Neuropsychiatric Diseases,
85NEUROIMAGE 948 (2014); for tDCS in healthy populations, see Brian A. Coffman, Vincent P. Clark&Raja
Parasuraman,Battery PoweredThought: Enhancement of Attention, Learning, andMemory in Healthy Adults Us-
ing Transcranial Direct Current Stimulation, 85 NEUROIMAGE 895 (2014). Note, however, that a few recent
studies have questionedwhether tDCS has any effect in healthy subjects, see eg JaredCooneyHorvath, Jason
D. Forte &Olivia Carter, EvidenceThat Transcranial Direct Current Stimulation (tDCS) Generates Little-to-No
Reliable Neurophysiologic Effect Beyond MEP Amplitude Modulation in Healthy Human Subjects: A Systematic
Review, 66 NEUROPSYCHOLOGIA 213 (2015).
3 Anita Jwa, Early Adopters of the Magical Thinking Cap: A Study On Do-It-Yourself (DIY) Transcranial Direct
Current Stimulation (tDCS) User Community, 2 J. L. BIOSCI., 292, 307 (2015).
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academic field.4 Researchers have publicly voiced their concerns: a 2013Nature edito-
rial stated that ‘to try toboost cognitiveperformance in thiswaymight be a verybad idea
indeed’.5 One tDCS researcher published a letter inNature titled ‘Transcranial devices
are not playthings’ writing: ‘Unorthodox technologies and applications must not be al-
lowed to distort the long-term validation of tDCS’.6 In addition, scientists have urged
caution regarding the uncontrolled use of tDCS: although no serious adverse events
have been reported among the 10,000 subjects studied to date,7 at least one study has
found that tDCS can impair cognitive function in some individuals.8
Currently, tDCS is not approved in the United States by the Food and Drug
Administration (FDA) as a medical treatment for any indication. Researchers (but
not the general public) may obtain tDCS devices for investigational use from either
Soterix or Neuroconn, the two US companies whose devices have an ‘investigational
device exemption’ from theFDA.9 However, as theSoterix andNeuroconnmodels cost
thousands of dollars, some researchers have opted to repurpose cheaper iontophoresis
devices (current-providingmachines used to treat various conditions, such as excessive
sweating) for tDCSuse. By contrast, consumer tDCSdevices—which are not regulated
as medical or investigational devices—are available to the public; there are currently at
least a half dozen devices on the market ranging in price from $49 to $299.
Several scientists and neuroethicists have argued that there is a need for addi-
tional regulation to cover consumer tDCS devices.10 One paper proposed extending
medical device regulation in Europe to include not just tDCS devices but also con-
sumer electroencephalography (EEG) devices, which passively record electrical brain-
waves and display them to users.11 (I focus here only on non-invasive electrical brain
stimulation devices, because as has been previously pointed out, EEG devices in them-
selves are measuring tools, akin to heart-rate monitors.)12 Some scholars have written
extensively about the moral and ethical considerations related to non-invasive brain
4 According to the results of a questionnaire distributed at the 2015 New York City Neuromodulation
Conference, researchers believe that one of the main issues facing the field over the next 15 years
is the ‘DIY community ruining it for the rest of us’. Conference Questionnaire Results, Presented
on Jan. 11, 2015 at the New York City Neuromodulation Conference, New York, Jan. 9–11, 2015;
http://neuromodec.com/events/nyc-neuromodulation-conference-2015/ (accessed Aug. 25, 2015).
5 Editorial, Brain Blast, 498 NATURE 271, 272 (2013).
6 Marom Bikson, Sven Bestmann&Dylan Edwards,Neuroscience: Transcranial Devices Are Not Playthings, 501
NATURE 167 (2013).
7 Felipe Fregni et al., Regulatory Considerations for the Clinical and Research Use of Transcranial Direct Current
Stimulation (tDCS): Review and Recommendations from an Expert Panel, 32 CLIN. RES. REGUL. AFF., 22, pub-
lished online first Dec. 2 2014.
8 Amar Sarkar, AnnDowker &Roi Cohen Kadosh,Cognitive Enhancement or Cognitive Cost: Trait-Specific Out-
comes of Brain Stimulation in the Case of Mathematics Anxiety, 34 J. NEUROSCI. 16605 (2014).
9 Fregni et al., supra note 7 at 10. See also Soterix Medical, http://soterixmedical.com/tdcs and Jali Medical
(US distributor for Neuroconn) http://www.jalimedical.com/neuroconn dc stimulator mc.html (accessed
Sep. 22, 2015).
10 See eg Veljko Dubljevic, Neurostimulation Devices for Cognitive Enhancement: Toward a Comprehensive Reg-
ulatory Framework, 8 NEUROETHICS 115 (2015); Hannah Maslen et al., Do-it-Yourself Brain Stimulation: A
Regulatory Model, 41 J. MED. ETHICS 413 (2015).
11 Hannah Maslen et al.,The Regulation of Cognitive Enhancement Devices: Extending the Medical Model, 1 J. L.
BIOSCI. 68 (2014).
12 Andreas Kuersten & Roy H. Hamilton,The Brain, Cognitive Enhancement Devices, and European Regulation, 1
J. L. BIOSCI. 340 (2014).
672  A pragmatic analysis of the regulation of consumer TDCS devices
stimulation.13 Others have argued that there is a need for greater engagement with the
DIY brain stimulation community.14 Collectively, existing scholarship has contributed
important normative and ethical perspectives on the regulation of such devices.
Missing from this literature, however, are accounts that consider the practicalities of
the law and how it applies to existing and foreseeable consumer brain stimulation de-
vices. For example, as I will show in Part I below, an examination of the current tDCS
consumer device market reveals that the recommended extension of medical device
regulation in Europe would apply to only a small sliver of devices, rendering it largely
ineffective.15 Furthermore,manyproposals neglect to consider the practical differences
between regulation and regulatory enforcement.Though an ideal model of the law en-
visions all regulations as being consistently and equally enforced, a more realistic view
takes into account the resource-constrained nature of government bodies, who must
formally, and sometimes informally, prioritize regulatory enforcement and often do so
in unclear or unsystematic ways. Thus, before calling for additional regulation or con-
cluding that there is a ‘regulatory gap’,16 it must first be determined that the problem is
the lack of regulation, not the lack of enforcement.
It is also crucial to consider the precise statutory language of existing regulation. For
example, in theUnited States, the FDAmakes its determination of whether a product is
amedical device based on the intended useof the device as stated by themanufacturer—
notbasedon themechanismof actionof thedevice itself.One recent paper co-authored
by tDCS experts failed to take into account the intricacies of the statute, stating that it
would be ‘logical to include tDCS devices’ as medical devices according to the FDA,
regardless of ‘whether indicated for medical treatments, diagnostic purposes, wellness
aids, entertainment devices, or any other purpose. . . ’.17 However, legal authority carves
up jurisdictionmuchmore finely than this logic suggests.Within current statutory defi-
nitions, productsmarketed for entertainment orwellness purposeswould not fall under
the scope of the FDA (as long as theymake nomedical-related claims aboutmodifying
the structure or function of the body, as will be discussed in Part II below), whereas
a device intended for medical treatment or diagnosis would indeed be regulated as a
medical device.
This paper contributes to the literature on the regulation of consumer brain stim-
ulation devices in the USA by providing a fact-based analysis of the consumer tDCS
market and relevant laws and regulations. In the first section, I present a short his-
tory of the DIY tDCS movement and the subsequent emergence of DTC devices. In
the second and third sections, I outline the basics of FDA medical device regulation
and discuss how the definition of a medical device—which focuses on the intended use
of the device rather than its mechanism of action—is of paramount importance for
13 See eg Roy Hamilton, Samuel Messing & Anjan Chatterjee, Rethinking the Thinking Cap: Ethics of Neural
Enhancement Using Noninvasive Brain Stimulation, 76 NEUROLOGY 187 (2011); Roi Cohen Kadosh et al.,The
Neuroethics of Non-Invasive Brain Stimulation, 22 CURR. BIOL. R108 (2012).
14 Nicholas S. Fitz & Peter B. Reiner, The Challenge of Crafting Policy for Do-It-Yourself Brain Stimulation, 41
J. MED. ETHICS 410 (2015).
15 AnnaWexler,The Practices of the Do-It-Yourself Brain Stimulation Community: Implications for Regulatory Pro-
posals and Ethical Discussions, J. MED. ETHICS, DOI:10.1136/medethics-2015-102704.
16 Veljko Dubljevic, Victoria Saigle & Eric Racine,TheRising Tide of tDCS in the Media and Academic Literature,
82 NEURON 731, 736 (2014).
17 Fregni et al., supra note 7 at 2.
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discussions of consumer tDCS device regulation. I then discuss how both the FDA and
the courts have understood the FDA’s jurisdiction over medical devices in cases where
the meaning of ‘intended use’ has been challenged. In the fourth section, I analyse the
only instance of tDCS regulatory action to date, in which the California Department
of Public Health (CDPH) forced a firm to recall several hundred consumer tDCS de-
vices. Although there exists a common perception that the FDA has not been involved
with the regulation of consumer tDCS devices, the California case demonstrates that
the CDPH’s actions were instigated by an FDA engineer. Finally, I discuss the multi-
ple US authorities, other than the FDA, that can regulate consumer brain stimulation
devices.
In sum, this paper dispels the notion of a ‘regulatory gap’ with regard to consumer
non-invasive brain stimulation (in theUnitedStates). Several papers—mostly those fo-
cusing on the appropriate ‘level’ of regulation—seem to have assumed that additional
regulation is the de facto appropriate response to the existence of consumer tDCS de-
vices. I argue, however, that there already exists a comprehensive regulatory framework
for both consumer and medical tDCS devices in the United States. Thus, rather than
calling for additional regulation, I suggest the need for a practical approach to consumer
brain stimulation devices, one that outlines relevant issues of concern and considers
multiple ways of addressing them.
I. FromDIY toDTC—a short history of the consumer tDCS devicemarket
The earliest mentions of DIY brain stimulation date back to 2007, in an online forum
posting on Longecity.org18 and in an articleThe Phoenix, which described how one in-
dividual tried to treat his depression using a tDCS device he constructed by modifying
a Radio Shack Electronics Learning Lab.19 Home use of tDCS seems to have remained
isolated until mid-2011, when a Yahoo group20 and a Reddit forum (called a ‘subred-
dit’) dedicated to DIY tDCS were formed.21 By early 2012, there were a number of
blogs and sites dedicated exclusively to the topic, indicating that individuals were uti-
lizing tDCS for both self-treatment and cognitive enhancement purposes.
What factors contributed to the rise ofDIY tDCS?Theappearance of themovement
corresponds to the increase in popularity of tDCS in scientific journals: in 2011, there
were over 130 peer-reviewed articles about tDCS, more than double that of the pre-
vious year.22 The following year, 2012, saw the greatest quantitative increase in men-
tions of tDCS in the popular press.23 In addition, DIY tDCS shares characteristics
with related movements that were well established by 2010, such as DIY biology and
18 Attaching a battery to your head,LONGECITY, 2007, http://www.longecity.org/forum/topic/19346-attaching-
a-battery-to-your-head/ (accessed Sep. 22, 2015).
19 PaganKennedy,Brain-O-Matic, BOSTONPHOENIX, Feb. 7, 2007, http://thephoenix.com/boston/life/33313-
brain-o-matic/ (accessed Sep. 22, 2015).
20 Yahoo Transcranial Direct Current Stimulation group, https://groups.yahoo.com/neo/groups/tDCStim/
info (accessed Sep. 22, 2015).
21 Reddit /r/tDCS (http://www.reddit.com/r/tDCS/) began inApril 2011. E-mail frommoderator of r/tDCS
to AnnaWexler (Feb. 17, 2015), on file with author.
22 Supra note 1.
23 According to one study, there were roughly three-dozen print media articles about tDCS in 2011, and nearly
70 in 2012. See Dubljevic et al., supra note 16, at 732.
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quantified self.24 Finally, and perhapsmost importantly, although there are othermeth-
ods of stimulating the brain with electricity or magnetism, tDCS is unique in that the
stimulation device is both non-invasive (ie no surgical implantation is required) and
relatively inexpensive to acquire or create.25
During the early days of the DIY tDCS, most individuals built their devices from
scratch, with the help of diagrams posted online and electronics assistance from other
DIYers. At its core, a tDCS device contains a current-providing component (such as
a 9 V battery), wires that plug into the current source, and electrodes that interface
between the wire and the skin. When both electrodes are connected to the scalp, the
electrical circuit closes, and current is thought to flow through the brain.26 This sim-
ple construction—battery, wires, and electrodes—forms the essence of a tDCS device.
Compared to other techniques that stimulate the brain with electricity, such as elec-
troconvulsive therapy (ECT), the level of current used in tDCS is relatively low: most
tDCS studies use 0.5–2 mA, whereas ECT utilizes 500–900 mA.27
The notion of a ready-to-wear consumer tDCS headset first hit the media in the
spring of 2012, when two undergraduates from the University ofMichigan,Matt Sorn-
son and Nick Woodhams, built a prototype of a tDCS device called the GoFlow (‘the
world’s first tDCS kit’) and promised to sell it for $99.28 Various press outlets picked
up on the story, enthusiastically describing the initiative with headlines such as ‘Buy a
DIY Brain Supercharger for $100’ and ‘Transcranial direct current stimulation works,
and you can try it at home’.29 Twomonths later, inMay 2012, the company announced
that theywere being delayed due to FDA concerns,30 and in early 2013 the co-founders
made the decision to abandon plans for the headset.31 Rumors swirled online that the
GoFlow team ‘ran into some problems’ with the FDA.32 But Sornson had not been
24 Both DIY Biology andDIY tDCS embody what has become known as the maker culture, which places a high
value on tinkering, engineering, and creating things from scratch. For DIY Biology, see eg http://diybio.org/
and ALESSANDRO DELFANTI, BIOHACKERS: THE POLITICS OF OPEN SCIENCE (2013). Both DIY tDCS and the
quantified self-movement share the same underlying goal of self-improvement and self-optimization; see eg
Melanie Swan,The Quantified Self: Fundamental Disruption in Big Data Science and Biological Discovery 1 BIG
DATA 85, 87 (2013).
25 By comparison, deep brain stimulation, a treatment for Parkinson’s disease that provides electrical stimula-
tion to the brain, requires neurosurgery. Transcranial magnetic stimulation, an FDA-approved treatment for
depression, is non-invasive, but the stimulation device is not easy to replicate.
26 For a view that current is not entering the cortex and only affecting cranial nerves, see William J. Tyler
et al., Suppression of Human Psychophysiological and Biochemical Stress Responses Using High-Frequency Pulse-
Modulated Transdermal Electrical Neurosignaling, BIOXRIV preprint, first published online Feb. 8, 2015,
doi.org/10.1101/015032
27 American Psychiatric Association,The Practice of ElectroconvulsiveTherapy: Recommendations for Treat-
ment, Training and Privileging, 147 (2d ed. 2000).
28 GoFlow, http://www.flowstateengaged.com (accessed Mar. 2012). http://web.archive.org/web/
20120314201106/http://flowstateengaged.com/
29 Ashlee Vance, Buy a DIY Brain Supercharger for $100, BLOOMBERG BUSINESSWEEK, Mar. 21, 2012,
http://www.businessweek.com/articles/2012-03-21/buy-a-diy-brain-super-charger-for-100 (accessed
Sep. 22, 2015); Christopher Mims, DIY Kit Overclocks Your Brain With Direct Current, MIT TECHNOLOGY
REVIEW,Mar. 8, 2012, http://www.technologyreview.com/view/427177/diy-kit-overclocks-your-brain-with
-direct-current/ (accessed Sep. 22, 2015).
30 Go Flow Kickstarter Campaign Denied, DIYTDCS, http://www.diytdcs.com/2012/05/goflow-kickstarter-
campaign-denied/ (accessed Dec. 14, 2013).
31 Interview withMatt Sornson, co-developer of GoFlow, Feb. 14, 2014.
32 Longecity Forum, http://www.longecity.org/forum/topic/57869-increased-cognition-with-9v-battery/
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contacted by the FDA; rather, he andWoodhams abandoned the GoFlow for personal
reasons, though potential future complications with the FDAwere also a factor in their
decision.33Thecompanyquietly sold theirmailing list anddomainname to afirmbuild-
ing a consumer tDCS device called the Foc.us,34 and in June 2013 announced that they
would not be moving forward with the project.35
In the year between Sornson’s and Woodham’s start up and shut-down announce-
ments, a number of other consumer tDCS devices appeared on the market: Hong
Kong-based Trans Cranial Technologies36 began selling a $379 device, and at least
three other websites offered more affordable tDCS device ‘kits’.37 The kits varied in
both price and level of sophistication, but usually consisted of a 9 V battery enclo-
sure (or a snap connector that the battery attached to), wires, electrodes, and a head-
band to facilitate electrode placement. They were seemingly geared to those who had
knowledge of tDCS but lacked the necessary soldering skills to build their own device
from scratch. Some home users, like scientists, began purchasing and repurposing ion-
tophoresis devices, which legally require a prescription but in practice are widely avail-
able online.38
The Foc.us device, which was released in the summer of 2013, was arguably the first
true DTC tDCS device.39 With its sleek, ready-to-wear headset design, it looked more
like Google Glass than a cobbled-together DIY device. The company’s website, ad-
vertising campaign (featuring photos of an attractive woman wearing the device), and
promised smartphone integrationmade it clear that the product was a step up from the
kits sold by small-scale vendors. Though the Foc.us device was ostensibly marketed to
gamers, its release thrust the DIY tDCS movement into the spotlight and brought the
debate over the regulation of cognitive enhancement devices to public attention.40
Since 2013, thousands of Foc.us devices have been sold41 and the company has re-
leased a second generation of products; it currently has a headset specially designed
for exercise.42 New consumer tDCS devices are constantly appearing on the market,
33 E-mail fromMatt Sornson, co-developer of GoFlow, to AnnaWexler (Dec. 15, 2013), on file with author.
34 Supra note 31.
35 Id. andNews from GoFlow! Good and Bad, DIYTDCS, http://www.diytdcs.com/2013/06/news-from-goflow-
good-and-bad/ (accessed Dec. 14, 2013).
36 Trans Cranial Technologies, http://www.trans-cranial.com/ (accessed July 1, 2014); note that the company
is currently conducting business as TCT Research Limited.
37 See www.biocurrentkit.com, www.tdcs-kit.com, and www.tDCSdevicekit.com, accessed between Dec. 2012
and Apr. 2013, archived versions at http://web.archive.org
38 See eg http://www.amazon.com/DSS-Chattanooga-Ionto/dp/B00FC2SRMY and http://www.
isokineticsinc.com (accessed Sep. 22, 2015).
39 FOC.US, Transcranial Direct Current Stimulation for Gamers, http://www.foc.us/ (accessed July 8, 2013),
http://web.archive.org/web/20130708144009/http://www.foc.us./
40 See eg Kate Murphy, Jump-Starter Kits for the Mind, THE NEW YORK TIMES, Oct. 28, 2013,
http://www.nytimes.com/2013/10/29/science/jump-starter-kits-for-the-mind.html (accessed Sep.
22, 2015); Nick Statt,WhenWearable Tech Makes You Smarter—by Zapping Your Brain, CNET, Aug. 9, 2013,
http://news.cnet.com/8301-11386 3-57597116-76/when-wearable-tech-makes-you-smarter-by-zapping-
your-brain/ (accessed Sep. 22, 2015).
41 Although sales data for the Foc.us device are not public, the company sold out its first production run of 3000
within a month (Murphy supra note 40) and has since had several production runs.
42 Foc.us edge tDCS headset, http://www.foc.us/edge-tdcs-headset (accessed Jan. 25, 2015).
676  A pragmatic analysis of the regulation of consumer TDCS devices
most often manufactured in small runs by individuals interested in, or involved with,
the DIY tDCS movement. Though the prospect of regulation looms large for many of
these manufacturers, the only legal action to date has come at a state level, from the
CDPH, which effectively halted sales from tdcsdevicekit.com inMay 2013 (the case is
discussed in detail in Part IV below).
In 2014, two Silicon Valley start-ups announced that they were entering the con-
sumer brain stimulation device market. One company, Halo Neuroscience, issued a
press release in May 2014, noting that it had received $1.5 million in venture capital
funding and was developing ‘wearable technology that boosts brain function’.43 The
company’s board includes well-known names such as Reed Hundt, former chairman
of the Federal Communications Commission (FCC).44 In October 2014, a company
named Thync announced that it had raised $13 million in venture capital funding.45
In June 2015, the company released its device ($299), which is controlled via smart-
phone and provides a form of non-invasive brain stimulation for mood alteration pur-
poses (either a ‘calm vibe’ or an ‘energy vibe’).46 The company has reportedly tested
thousands of subjects, both on its own and in collaboration with tDCS researchers,
and has posted some of its results online.47 Given that both Halo Neuroscience and
Thync are well funded and highly connected, consumer non-invasive electrical brain
stimulation is certain to hit the mainstream public in the near future.Thus, what began
as DIY brain stimulation is likely to be superseded by—or at least dwarfed by—DTC
brain stimulation.
At present, however, the border between DIY and DTC remains muddled. Quali-
tative research has shown that while some individuals from the DIY tDCS movement
build their owndevices, others acquire awide rangeof devices, fromdevice ‘kits’ (which
require assembly) and iontophoresis devices (which require repurposing) to theFoc.us
headset.48 Given the variation in existing consumer tDCS devices, the consumer non-
invasive brain stimulation market does not lend itself easily to regulation. Indeed, the
proposed extension of medical device regulation in Europe would apply only to true
DTC headsets; it would not encompass self-built devices and iontophoresis devices,
and it is unclear whether it would cover ‘kits’.49 Furthermore, if the devices fromThync
andHalo Neuroscience are sold at competitive price points, it is possible that the mar-
ket may take care of itself. That is, absent a material price difference, consumers will
opt for the safest andmost effective product. As companies such asThync have already
43 Halo Neuroscience—Press Release (May 28, 2014) http://haloneuro.com/press/ (accessed Jan. 25, 2015).
44 Halo Neuroscience, http://haloneuro.com/ (accessed Jan. 25, 2015).
45 Brad Stone, Thync Lets You Give Your Mind a Jolt, BLOOMBERG BUSINESS, Oct. 8, 2014,
http://www.bloomberg.com/bw/articles/2014-10-08/thync-raises-13-million-for-its-brain-stimulating-
electrodes (accessed Sep. 22, 2015).
46 Id. andThync.com (accessed Sep. 22, 2015).
47 The safety section of Thync’s website states: ‘Thync Vibes were safely tested on several thousand in-
dividuals under a variety of conditions to optimize their performance and comfort.’ Thync—Safety,
http://www.thync.com/science-and-technology (accessed June 25, 2015). See also Tyler et al., supra note
26.
48 Jwa, supra note 3; Wexler, supra note 15.
49 Wexler, supra note 15.
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been in dialog with the FDA,50 it is unclear how additional regulation—which could
take years to implement—might fit into the overall picture.
II.The importance of ‘intended use’ for FDAmedical device regulation
Prior to 1976, medical devices were not required to secure FDA approval before being
marketed.51 But after a series of tragedies related to the implantation of pacemakers and
intra-uterine devices,52 Congress passed the Medical Device Amendments in 1976,53
which set up a new regulatory scheme for devices, classifying thembased on risk level.54
Class I devices are low-risk devices, such as band-aids and examination gloves, which
are subject to ‘general controls’ (eg registration of facilities, device labeling, compli-
ance with good manufacturing practices).55 Class II devices are moderate risk devices,
such as surgical drapes and breast pump kits, and are subject to additional ‘special con-
trols’ that vary by product (eg performance standards, special labeling, and post-market
surveillance).56 To date, most devices that provide a low level of electrical stimulation
to the body for medical purposes, such as transcutaneous electrical nerve stimulation
(TENS) devices and powered muscle stimulation devices, are considered Class II de-
vices.57 Class III devices are those that pose a high risk of illness or injury.58 The only
Class III non-invasive electrical stimulation devices are cranial electrotherapy stimula-
tion (CES) devices and some iontophoresis devices, though in 2014 the FDA indicated
that it planned to recategorize both as Class II.59 Prior to being marketed, a new class
III device must submit a premarket application (PMA) demonstrating safety and ef-
ficacy for a specific indication.60 The PMA process, which is similar to the new drug
approval process, is often a multi-year, multi-million dollar endeavor.Thus, most med-
ical device manufacturers take a faster and cheaper path to market, by filing a 510(k)
application to demonstrate ‘substantial equivalence’ to a ‘predicate’ device.61 In 2011,
nearly 99 per cent of newmedical devices were cleared by the FDA through the 510(k)
50 Infra notes 84 and 85.
51 PETER BARTONHUTT ET AL.., FOOD AND DRUG LAW, 1201 (4d ed. 2014).
52 Id. at 1202, 1205.
53 Medical Device Amendments of 1976, Pub.L. No. 94–295, 90 Stat. 539.
54 21 U.S.C. § 360c(a)(1) (2012).
55 Id. and US Food and Drug Administration, Regulatory Controls (Medical Devices), http://www.fda.gov/
MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/ucm2005378.htm
(accessed Sep. 22, 2015).
56 Id.
57 See Fregni et al., supra note 7, at 2; and eg 21 C.F.R. §882.5890, §882.5891, and §882.5810 (2015).
58 21 U.S.C. § 360c(a)(1) (2012).
59 For CES devices, see Food and Drug Administration, 79 Fed. Reg. 33,712 (June 12, 2014) (codified at 21
C.F.R. 882), https://www.federalregister.gov/articles/2014/06/12/2014–13756/neurological-devices-
withdrawal-of-proposed-effective-date-of-requirement-for-premarket-approval-for (accessedSep. 22, 2015).
See also infra notes 63 and 128. For iontophoresis devices, see Food and Drug Administration, 79 Fed.
Reg. 56,532 (proposed Sept. 22, 2014) (to be codified at 21 C.F.R. pt. 890), https://www.federalregister.
gov/articles/2014/09/22/2014–22453/reclassification-of-iontophoresis-devices-intended-for-any-other-
purposes.
60 21 U.S.C. § 360c(a)(1) and US Food and Drug Administration, Premarket Approval,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/
PremarketSubmissions/PremarketApprovalPMA/ucm2007514.htm (accessed Jan. 25, 2015).
61 Section 510(k) of the Federal Food, Drug, and Cosmetic Act (FFDCA) (21U.S.C. § 360(k)) (2012) and 21
CFR § 807.92(a)(3) (2015).
678  A pragmatic analysis of the regulation of consumer TDCS devices
process.62 Note, however, that most new Class III devices (which require PMAs) can-
not be cleared via the 510(k) process.63
While the level of risk determines the regulatory process for medical devices, a
product must first meet the definition of a medical device to fall within the
regulatory jurisdiction of the FDA. According to Section 201(h) of the Food,
Drug & Cosmetic (FD&C) Act, a medical device is:
 an instrument, apparatus, implement, machine, contrivance, implant, in
vitro reagent, or other similar or related article, including a component
part, or accessory which is:
 recognized in the official National Formulary, or theUnited States Pharma-
copoeia, or any supplement to them,
 intended for use in the diagnosis of disease or other conditions, or in
the cure, mitigation, treatment, or prevention of disease, in man or other
animals, or
 intended to affect the structure or any function of the body of man or other
animals, andwhich does not achieve its primary intended purposes through
chemical action within or on the body of man or other animals and which
is not dependent upon being metabolized for the achievement of any of its
primary intended purposes.64
Importantly, the definition of amedical device is not based on themechanism of action
of the device, but rather on its intended use: a product is amedical device if it is intended
for use in diagnosis or treatment, or intended to affect the structure or function of the
body. Similar wording appears in the definition of a drug, and ‘intended use’ language
dates all the way back to the Federal Food and Drugs Act of 1906.65
How does the FDA establish intended use? According to the code of federal reg-
ulations Title 21, part 801, subpart A, Section 801.4 (‘meaning of intended uses’), it
focuses on ‘the objective intent of the persons legally responsible for the labeling of
62 Hutt et al., supra note 51, at 1219 (‘In 2011, FDA cleared 3,072 premarket notifications while approving only
37 PMAs. In other words, approximately 98.8 percent of new devices cleared for marketing by FDA that year
were cleared under section 510(k) rather than by PMA.’).
63 The only case wherein new Class III devices can be cleared via the 510(k) process is if the devices are
substantially equivalent to certain ‘preamendment’ (ie introduced to the market before May 28, 1976) Class
III devices. When the new regulatory scheme for medical devices took effect in the late 1970s, the FDA
temporarily classified over 100 devices as Class III devices. Such devices were never required to submit
PMAs showing safety or efficacy. It has taken the FDA several decades to ‘reclassify’ these devices—either
into Class I or Class II, or sustain the Class III classification but require a PMA—and currently there are
less than 20 such devices awaiting FDA action. Thus, if a new (‘postamendment’) device can demonstrate
substantial equivalence to one of the few devices that were temporarily classified as Class III devices and
have yet to be reclassified, the device can be cleared via the 510(k) process. See infra note 128 and related
text for the discussion of one example, a CES device. US Food And Drug Administration, 515 Program Ini-
tiative, http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/
CDRHTransparency/ucm240310.htm (accessed Sep. 22, 2015).
64 Section 201(h) of the FFDCA (21 U.S.C. § 321(h)) (2012); guidance to industry http://www.fda.gov/
MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevice/ucm051512.htm
(accessed Sep. 22, 2015).
65 Section 6, 34 Stat. 768, 769 (1906).
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devices’ as shown on both the product’s labels and advertising.66 That is, the product is
classified according to the manufacturer’s representation of it. Thus, to a large extent,
manufacturers canmaintain control over how their products are regulated. Indeed, this
was the legislative intent: a 1935Senate report noted that the ‘manufacturer of a laxative
which is amedicated candy or chewing gum can bring his product within the definition
of drug and escape that of food by representing the article fairly and unequivocally as a
drug product’.67
A product’s classification as a drug or device can have far-reaching consequences: as
mentioned above, new drugs (and many new devices, if they cannot demonstrate sub-
stantial equivalence to a predicate device)must undergo costly clinical trials to demon-
strate safety and efficacy, and it often takes several years to obtain FDA approval. In
some industries, such as cosmetics, which have lenient regulatory requirements as com-
pared todrugs,manufacturers take great pains to ensure that their advertising andprod-
uct labels do not make disease or structure/function claims. It is no exaggeration to
say that a manufacturer’s fate may hinge on specific word choices. In the classic exam-
ple, a cream that claims to ‘reduce wrinkles’ will be classified as a drug (and subject to
stringent regulatory requirements) because the wording makes a specific struc-
ture/function claim, but a cream that claims to ‘reduce the appearance of wrinkles’
will be classified as a cosmetic because the language makes a beautification claim, not a
structure/function one.68
Given the importance of intended use claims for the classification of drugs and de-
vices, it is worthwhile to examine how manufacturers of consumer tDCS devices have
represented their products. As can be seen in Table 1, the overall intended use implied
by most manufacturers (based on their websites) is related enhancement or optimiza-
tion of brain function. Two manufacturers (TCT Research Limited69 and PriorMind,
both based in Hong Kong) make explicit disease claims about their products. Several
other manufacturers mention, or link to, studies on the therapeutic use of tDCS, while
others refrain from referring to any such research. One manufacturer, Super Specific
Devices, makes no claims at all.
66 The text of 21 C.F.R. § 801.4 reads as follows:
‘The words intended uses. . . refer to the objective intent of the persons legally responsible for the labeling of
devices. The intent is determined by such persons’ expressions or may be shown by the circumstances sur-
rounding the distribution of the article. This objective intent may, for example, be shown by labeling claims,
advertising matter, or oral or written statements by such persons or their representatives. It may be shown by
the circumstances that the article is, with the knowledge of such persons or their representatives, offered and
used for a purpose for which it is neither labeled nor advertised. The intended uses of an article may change
after it has been introduced into interstate commerce by its manufacturer. If, for example, a packer, distribu-
tor, or seller intends an article for different uses than those intended by the person from whom he received
the devices, such packer, distributor, or seller is required to supply adequate labeling in accordance with the
new intended uses. But if a manufacturer knows, or has knowledge of facts that would give him notice that a
device introduced into interstate commerce by him is to be used for conditions, purposes, or uses other than
the ones for which he offers it, he is required to provide adequate labeling for such a device which accords
with such other uses to which the article is to be put.’
67 This Senate report accompanied one of precursor bills to the FD&C. S.Rep. No. 493, 73dCong., 2d Sess. 2–3
(1934), reprinted in 2 Legislative History, 721, 722–23.
68 For comprehensive discussion, see Peter BartonHutt,TheLegal Distinction in the United States Between a Cos-
metic and a Drug, in COSMECEUTICALS 223, 240 (Peter Elsner &Howard I. Maibach eds., 2000).
69 TCT Research Limited previously conducted business as TCTTechnologies, see supra note 36, but its web-
site (www.trans-cranial.com) remained the same.
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Table 1.Marketing language from thewebsites of consumer tDCS devices available
for purchase as of June 2015.
CONSUMER TDCS DEVICE MARKETING LANGUAGE
Brain Stimulator∗
https://thebrainstimulator.net/what-is-tdcs/










‘Be happier. Be focused. Be smarter’
Foc.us∗
http://www.foc.us/
‘make your synapses fire faster’,
‘overclock your brain’, ‘take charge’
Thync∗
http://www.thync.com
‘quiet your mind’, ‘boost your workout’
PriorMind
http://www.priormind.com
‘increase your attention span’
‘tDCS has been widely used to treat
depression. . . ’
TCT∗
http://www.trans-cranial.com





∗Website contains some form of a medical or health-related disclaimer.
Furthermore, it seems that at least some manufacturers have attempted to write
around the provisions of the FDA. Seven of the nine manufacturers display some form
of health or medical-related disclaimer on their websites, noting either that their prod-
uct is not a medical device or that it is not intended to cure, treat, or diagnose diseases.
To date, at least two manufacturers of tDCS devices have used the term ‘kit’ in hopes
that it would put distance between their product and the FDA’s definition of a medical
device.70
While products that make explicit or implied disease claims would be classified as
medical devices, it is less clear whether those that mention, or link to, tDCS research
could be consideredmedical devices. For example, while a link to a study describing the
benefits of tDCS for depression may be considered an implied medical claim, noting
that scientists are studying the use of tDCS for various indications may not be. Each
manufacturer’s claim and product would have to be reviewed in their own contexts.
70 Richard O’Rourke of www.tDCSdevicekit.com (which does not appear in Table 1 because it shut down in
2013) stated this to a California Department of Health investigator, see Part IV andMedical Device Investiga-
tive Report, infra note 116. A manufacturer of one of the device kits in Table 1 stated: ‘I came up with the
idea of a kit, skirting the line a little bit. . . it’s a kit. . . it’s not a TDCS device’. Interview with manufacturer
(Mar. 27, 2014).
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Although such individual reviews are outside the scope of this paper, the issue of im-
plied therapeutic claims is considered again in Part IV, in the discussion of the regu-
latory enforcement action taken by the CDPH against a small-scale consumer tDCS
manufacturer.
The more complex question, however, is whether language such as ‘power your
mind’ and ‘increase your attention span’ implies an intended structure/function claim.
The FDA and courts have struggled to interpret the meaning of ‘intended to affect the
structure or any function of the body. . . ’ as a large number of products—from high-
heeled shoes to chairs to treadmills—can be said to be intended to affect the body’s
structure or function. In general, both the FDA and courts have recognized that inter-
preting the statute literally would lead to a large number of consumer products com-
ing under FDA regulation. For example, in one case, the D.C. Circuit court noted that
Congress surely did not mean for there to be a broad reading of ‘intended to affect
the structure or function. . . ’ because otherwise amultitude of products—anything that
‘stimulates the senses’—could be considered a medical device or drug.71
Instead, courts have leaned toward a narrow interpretation of the statute, in which a
structure/function claim must have a medical or therapeutic connotation.Three cases
in particular, related to seizures of wrinkle remover creams in the 1960s, have served
to clarify this interpretation. In United States v. An Article. . .Sudden Change, an appeals
court ruled that the question of whether a product is to ‘intended to affect the struc-
ture or function of the body’ hinged on whether the claim may be said ‘to constitute
a representation that the product will affect the structure of the body in some medi-
cal or drug-type fashion’.72 In United States v. An Article of Drug. . .Helene Curtis Magic
Secret, a district court also upheld that a ‘drug connotation’ was necessary for a claim
to be considered a structure/function one.73 In United States v. An Article of Drug. ..
Line Away, an appeals court ruled that the Line Away product was a drug, because
its structure/function claims had therapeutic implications.74 Though the latter three
cases relate to drugs, the ‘intended to affect. . . ’ clause is identical for drugs andmedical
devices.
Indeed, in a 2002 letter, FDAChiefCounselDanielTroy stated that theFood,Drug,
andCosmetic Act regulates only those devices whose claims havemedical or therapeu-
tic connotations.75 In the letter, which can be said to reflect the FDA’s most recent ex-
plication of its position on intended use and structure/function claims, the FDA deter-
mined that an implantable radio-frequency identification chip intended for health ap-
plicationswas considered amedical device,whereas the samechip intended for useonly
in security and personal identification applications was not.Thus, even an implantable
device—one that clearly affects the structure or functionof the body in somemanner—
was considered a medical device by the FDA only when its intended use was medically
related.
With regard to consumer tDCS devices, would ‘brain optimization’ or ‘cognitive
enhancement’ claims be considered to have medical or therapeutic connotations?
71 Action on Smoking and Health v. Harris, 655 F.2d 236, 240 (D.C. Circuit 1980).
72 United States v. An Article. .. Sudden Change, 409 F.2d. 734 (2d Cir. 1969).
73 United States v. An Article of Drug. . . Helene Curtis Magic Secret, 331 F. Supp. 912 (D. Md. 1971).
74 United States v. An Article of Drug. .. Line Away, 415 F.2d 369 (3d Cir. 1969).
75 Letter from FDAChief Counsel Daniel E. Troy to Jeffrey N. Gibbs (Oct. 17, 2002).
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Indeed, the issue of what sorts of ‘optimization’ claims are permissible for consumer
devices has become a pressing one in recent years, due to the increase in wearable tech-
nology devices and smartphone-based health applications. In at least some industries, it
is thought that ‘wellness’ claims (eg ‘supports sleep’) as opposed to therapeutic ones (eg
‘reduces insomnia’) will place a product outside the definition of a medical device. For
example, at the 2014 Neurogaming conference, a panel of neurotechnology investors
emphasized the importance of distinguishing between wellness and therapy claims for
avoiding FDA regulation.76 Indeed, many consumer EEG devices—which, as men-
tioned in the introduction, monitor rather than stimulate the brain’s activity—seem to
have strategically marketed their devices for ‘improvingmental fitness’ and ‘optimizing
brain performance’.77 However, it should be noted that the lack of formal enforcement
action on the part of the FDA in the consumer neurotechnology arena (ie with regard
to both tDCS and EEG devices) does not necessarily indicate that the FDA shares this
view.
To address the regulatory status of health-related wearable technology devices, the
FDA published a draft guidance on January 20, 2015, titled ‘General Wellness: Pol-
icy for Low Risk Devices’.78 Although guidances are non-binding, the FDA has in re-
cent years increasingly used them to reflect its latest thinking to industry. The draft
guidance—which, it should be emphasized, is not the final version of the guidance, nor
will it bebindingor enforceablewhen it is finalized—indicates that theFDAdoesnot in-
tend to enforce device provisions for ‘general wellness products’ presenting a low risk
to safety. The draft guidance defines a general wellness product in terms of intended
use claims: a general wellness product is one that makes claims related to ‘maintain-
ing or encouraging a general state of health’ without references to diseases or condi-
tions. Among the examples of acceptable wellness claims provided are those relating to
‘mental acuity’, ‘concentration’, ‘problem-solving’, and ‘relaxation and stress manage-
ment’.79 Furthermore, the draft guidance indicates that even certain structure/function
claims are permitted under the umbrella of ‘wellness claims’: examples of acceptable
claims include those related to improving muscle size, toning the body, enhancing car-
diac function, and improving sexual performance, among others.80 Thus, at first glance,
the draft guidance seems to indicate that the FDA does not intend to enforce regula-
tions for tDCS devices marketed for wellness purposes.
However, the draft guidance also provides a second criterion: the product must be
a low-risk device. According to the draft guidance, a product is not a low-risk device if
‘it involves an intervention or technology that may pose a risk to a user’s safety if device
controls are not applied’.81 The draft guidance also states that in determining whether
76 Neurogaming 2014, Investing in Neurogaming: Panel Discussion, May 7, 2014, video recording at
https://www.youtube.com/watch?v=fz95kEx3zx4.
77 See eg Muse, http://www.choosemuse.com/; Emotiv Insight, https://emotiv.com/insight.php; Neu-
rosky, http://neurosky.com/; Melon http://www.thinkmelon.com/; and FocusBand http://www.
ifocusband.com/ (accessedMarch 2015).
78 US Food And Drug Administration,General Wellness: Policy for Low Risk Devices Draft Guidance for Industry
and Food and Drug Administration Staff, Jan. 20, 2015, https://www.federalregister.gov/articles/2015/
01/20/2015-00756/general-wellness-policy-for-low-risk-devices-draft-guidance-for-industry-and-food-and
-drug (accessedMar. 1, 2015).
79 Id at 3.
80 Id at 4.
81 Id at 5.
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a device is low risk, the manufacturer should consider whether a similar device is ‘ac-
tively regulated’ by the FDA. Though the guidance provides a number of examples of
low-risk devices (mobile apps, wearable heart-ratemonitors) and non-low-risk devices
(cosmetic implants, laser technology products), electrical brain stimulation devices are
not mentioned. Would consumer tDCS products be classified as low-risk devices? On
the one hand, tDCS has been consistently shown to have relatively mild side effects
(eg surface skin burns, headaches, and dizziness).82 On the other hand, no serious or
chronic adverse events have been reported in the literature.83
The recent letter from theFDAtoThync regarding the classificationof its device sup-
ports the notion that the FDA does not view consumer neurotechnology devices that
have intended uses related to wellness or recreation as medical devices. Prior to going
to market,Thync submitted a 513(g), requesting information from the FDA regarding
how it would classify its product.84 According to the company, the FDA exempted the
product frommedical device requirements such as pre-market approval and clearance,
as the product was intended for recreational purposes.85 It should be noted, however,
that the same decision might not hold true for manufacturers who do not limit their
claims to recreational use. Furthermore, it is worth pointing out that the communica-
tion between the FDA andThync has not been made public; all information regarding
the FDA’s letter has come from the company itself.
Still, one question remains: if the definition of a medical device is based on its in-
tended use—and neither on risk level nor mechanism of action—could a consumer
device making only wellness or recreational claims (and not disease or medical-related
structure/function ones) fall under the scope of FDA regulation? Furthermore, how
can the draft guidance pose risk level as a criterion for regulation, if risk level only de-
fines the regulatory process once a device is considered to be within the jurisdiction of
the FDA? Answering these questions requires an examination of how courts have con-
strued the FDA’s statutory authority with regard to medical devices, which is the topic
of the next section.
III. Judicial interpretation of ‘intended use’ andmedical devices
When determining the intended use of a product, the FDA has historically relied al-
most exclusively onmanufacturers’ claims as represented on the product’s labeling and
82 AndreRBrunoni et al.,ASystematic Review onReporting andAssessment of Adverse Effects Associated with Tran-
scranial Direct Current Stimulation, 14 INT. J. NEUROPSYCHOPHARMACOL. 1133 (2011).
83 Fregni et al., supra note 7.
84 Interview with Jamie Tyler, CEO of Thync (Feb. 12, 2015). The company submitted a 513(g) ‘Request
for Information’ to the FDA, which is a ‘means of obtaining the agency’s views about the classifica-
tion and the regulatory requirements’ applicable to a particular device. See US Food and Drug Admin-
istration, Guidance for Industry and Food and Drug Administration Staff - FDA and Industry Procedures
for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act, Apr. 6, 2012,
http://www.fda.gov/RegulatoryInformation/Guidances/ucm209841.htm (accessed Feb. 26, 2015).
85 TheThync press release accompanying the launch of its device included the following statement: ‘Based on
its intended use in lifestyle applications, the FDA exempted the Thync System from medical device regula-
tions requiring pre-market notification (clearance) or approval’. Thync Press Release, Thync Launches First
Wearable to Shift Your State of Mind, Consumer Product Delivers Calm and Energy withinMinutes, June 2, 2015,
http://www.thync.com/resources/press-release/thync-launches-first-wearable-to-shift-your-state-of-mind
(accessed June 12, 2015).
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advertising.86 For example, in two cases from the 1950s, district courts upheld the focus
onmarketing claims, finding that cigarettesmaking disease prevention87 or weight-loss
claims88 came under the FDA’s jurisdiction, whereas cigarettes that lacked such claims
fell outside it. (Both of these cases came prior to the Medical Device Amendments of
1976, and the courts in each case considered the cigarettes to be drugs, not devices.)
Indeed, today there are many ‘dual use’ products that are identical in technology but
regulated differently based on intended use as represented by the manufacturer’s in-
tent. For example, exercise equipment marketed for medical purposes is regulated by
the FDA,89 but exercise equipment for recreational use is regulated by the Consumer
Product Safety Commission (CPSC).90 Other dual use products include bed rails,91
razors, and binoculars.92
Though the FDA has focused almost exclusively on marketing language to estab-
lish intended use, a close read of 21 C.F.R. Section 801.4 (‘meaning of intended uses’)
shows that the FDA can consider a variety of factors: intent may be shown by the ‘cir-
cumstances surrounding the distribution of the article’ or ‘oral and written statements’
by the manufacturers and their representatives.93 Indeed, the courts have affirmed the
FDA’s extensive powers in this regard: in one case, the Seventh Circuit upheld the
FDA’s reliance on instruction booklets, financial arrangements, and individuals’ tes-
timonies in determining the intended use of a product.94 In another, a district court
agreed that theFDAcould rely upon the ‘circumstances surrounding the distributionof
the article’ to determine that a product was a drug, even in the absence of explicit label-
ing.95 Furthermore, according to 21 C.F.R. Section 801.4, if the FDA can demonstrate
that the ‘article is, with the knowledge of such persons or their representatives, offered
and used for a purpose for which it is neither labeled nor advertised’, it can deem the
devicemisbranded.96 With these broad criteria, the FDAwould likely be well within its
authority to take action against many small-scale tDCSmanufacturers.
86 For a comprehensiveoverviewof intendeduse as it relates tomedical devices, seeGaryE.Gamerman, Intended
Use and Medical Devices: Distinguishing Nonmedical Devices from Medical Devices under 21 USC 321(h), 61
GEO. WASH. L. REV. 806 (1993). See also Hutt et al., supra note 51 at 92, 97.
87 United States v. 46 Cartons, More or Less, Containing Fairfax Cigarettes, 113 F. Supp. 336 (D.N.J 1953).
88 United States v. 354 Bulk Cartons. . . Trim Reducing-Aid Cigarettes, 178 F. Supp. 847 (D.N.J. 1959).
89 See eg 21 C.F.R §§ 890.5350–5410 (2015), defining various kinds of FDA-regulated exercise equipment as
those ‘intended for medical purposes’.
90 See Part V for further discussion of the Consumer Product Safety Commission.
91 US Food and Drug Administration, Bed Rail Safety: FDA and CPSC Activities, http://www.fda.gov/
MedicalDevices/ProductsandMedicalProcedures/HomeHealthandConsumer/ConsumerProducts/
BedRailSafety/ucm362867.htm (accessedMar. 20, 2015).
92 Gamerman supra note 86 at 833, 835, and n.182.
93 See supra note 66 for full text of 21 C.F.R § 801.4.
94 United States v. An Article of Device. . . Toftness Radiation Detector, 731 F.2d 1253, 1257 (7th Cir. 1984).
95 The product was a unlabeled balloon filled with nitrous oxide, and the ‘circumstances surrounding the distri-
bution’were that thedefendantswere sellingballoonsoutside a rock concert.Thecourt found this information
sufficient to establish intended use, andnitrous oxidewas therefore considered a drug.United States v. Travia,
180 F. Supp. 2d 115 (D.D.C 2001).
96 See supra note 66 for full text of 21C.F.R § 801.4.This particular line hasmost notably applied to the off-label
use of drugs: it is legal for physicians to prescribe a drug (or device) for an indication other than that for which
it has been approved by the FDA, but a manufacturer cannot advertise, label, or otherwise represent the drug
(or device) for a purpose other than approved by the FDA (21 C.F.R. § 801.4). This rule has been recently
challengedonFirstAmendment grounds: for review see StephanieM.Greene&LarsNoah,Debate:Off-Label
Drug Promotion and the First Amendment, 62 U. PA. L. REV. 239, 267 (2014).
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Even if a consumer tDCSdevicemakesnoexplicit or impliedmedical-related claims,
can the way that consumers actually use the product be sufficient to imply an intended
use?This question has previously been raised in cases regarding cigarette regulation.97
In the late 1970s, a citizen action group, Action on Smoking and Health (ASH), at-
tempted to compel the FDA to regulate cigarettes, arguing that the way in which con-
sumers actually used cigarettes demonstrated that the product’s ‘intended use’ was
to ‘affect the structure or function of the body’.98 The FDA refused to regulate, cit-
ing the absence of manufacturers’ health claims.99 In 1980’s Action on Smoking and
Health (ASH) v. Harris, the D.C. Circuit ruled that while it may be possible to demon-
strate intention by showing actual consumer use, the standard was high, as it had to be
shown that consumerswere using a product ‘nearly exclusively’ for a given intention.100
The court noted that ‘ASH did not establish, and arguably cannot establish, the near-
exclusivity of consumer use of cigarettes with the intent “to affect the structure or any
function of the body of man. . . ”’101 However, even if ASH had been able to demon-
strate that consumers were indeed using cigarettes exclusively to affect the structure or
function of the body, the court would have had to confront the question of whether the
structure/function use hadmedical or therapeutic connotations. Exercisemachines for
recreational purposes, for example, are used by consumers ‘nearly exclusively’ to affect
the structure or function of the body, yet they are not regulated as medical devices.
The question of whether the ‘actual and foreseeable use’ of cigarettes could be suf-
ficient to demonstrate an intended structure/function use was raised again in 1995,
when the FDA, under Commissioner David Kessler, attempted to regulate tobacco.102
The tobacco industry challenged the FDA, and the case ultimatelywent to the Supreme
Court.103 InFood andDrugAdministration v. Brown&Williamson (2000), theCourt re-
jected the FDA’s assertion of jurisdiction over cigarettes but did not address the ques-
tion of ‘actual and foreseeable use’ vs. ‘intended use’, and the matter has never been
subsequently resolved in court.104 However, it should be noted that in the 2002 letter
from the FDAChief Counsel mentioned in the previous section, the FDA took the po-
sition that ‘[f]oreseeability by the manufacturer does not suffice to establish intended
use’.105
Thus, intended use has most often been determined with relation to marketing
claims (although the FDA is fully within its power to consider a broad range of factors)
and ‘actual or foreseeable use’ has not been sufficient to determine intended use.While
the FDA and courts have favored a narrow interpretation of ‘intended use’, recognizing
that a literal reading of the structure/function definition would open up the door for
97 For overview, seeMargaret A. Boyd, ButtOut!!Why the FDA Lacks Jurisdiction to Curb Smoking of Adolescents
and Children, 13 J. CONTEMP. HEALTH LAW POL’Y, 169 (1997). See also Hutt et al. supra note 51 at 139, 145
(on struggles over tobacco regulation).
98 Hutt et al., supra note 51, at 140, and infra note 99.
99 See history as set out in Action on Smoking And Health v. Harris, 655 F.2d 236 (D.C. Cir. 1980).
100 Id. at 237.
101 Id.
102 Food and Drug Administration, 60 Fed. Reg. 41,314, (Aug. 11, 1995).
103 Hutt et al., supra note 51, 140, 141.
104 Food andDrug Administration v. Brown&Williamson Tobacco Corp. 529 U.S. 120 (2000). It was not until
Congress passed the 2009 Family Smoking Prevention and Tobacco Control Act (FSPTCA, Pub. L. No.
111–131) that tobacco came under the jurisdiction of the FDA.
105 Troy, supra note 75, at 5.
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a large number of consumer products to come under its jurisdiction, it is important to
note that courts are often willing to give deference to the FDA’s statutory interpreta-
tions. For example, in United States v. An Article of Drug. . . Bacto-Unidisk (1969), the
Supreme Court upheld the FDA’s decision to classify an antibiotic sensitivity disc as a
drug rather than a device, because doing so would subject the product to more strin-
gent requirements.106 TheCourt reasoned that Congress had not meant for the statute
to be read narrowly: rather, the FD&C Act ‘is to be given a liberal construction con-
sistent with the Act’s overriding purpose to protect the public health’.107 Subsequent
opinions, such as the dissent in Brown & Williamson, have quoted this line when rea-
soning in favor of a liberal interpretation of the FD&C Act.108 However, it is unlikely
that a similar ‘public health’ argument could be made with regard to consumer tDCS,
as it would have to be demonstrated that tDCS posed a significant public health risk—
and according to one recent empirical study, the home use of tDCS ‘does not seem to
pose an imminent risk or danger to the public’.109
Importantly, when attempting to both understand and predict the actions of the
FDA, it should be emphasized that the agency does not act consistently over time; in-
stead there is variation across different leaderships and agency actions. Thus, it is im-
possible to draw a single coherent picture of how the FDA (and courts) has acted. For
example, in at least one instance, the FDA seemed to contradict its stance that struc-
ture/function claims must be medically related: in July 2000, it sent a warning letter to
a companymarketing a battery-powered facial mask called Rejuvenique, which applied
electrical stimulation to the face. In the warning letter—which, it should be noted, is
not final agency action—the FDA wrote that regardless of the manufacturers’ claims,
‘because the Rejuvenique is intended to affect the structure or function of the body by
providing electrical current to various facial muscles to repeatedly contract them, it is a
device. . . ’.110 The company’s lawyers responded with a 15-page letter, arguing that the
product was not amedical device because the FDA classifies devices based on intended
use, not mechanism of action.111 Evidently, however, the company decided it was in
their best interest to work with the FDA rather than litigating, because one year later
the Rejuvenique was cleared via the 510(k) process.112
106 United States v. An Article of Drug. . .Bacto-Unidisk, 394 U.S. 784 (1969). The case took place prior to the
passage of theMedical Device Amendments, when devices, unlike drugs, did not have to undergo pre-market
approval.
107 Id. at 798.
108 In his dissent, Justice Breyer argued that cigarettes should indeed be regulated by the FDA, because (a) the
purpose of the FD&CAct is to protect public health; and (b) cigarettes are certainly are intended to affected
the structure or function of the body. Food andDrug Administration v. Brown&Williamson Tobacco Corp.
529 U.S. 120 (2000). (Breyer, J., dissenting).
109 See Jwa, supra note 3 at 25.
110 Larry D. Spears for Steven D. Niedelman, Acting Director, Office of Compliance, Food and Drug
Administration, Warning Letter to Salton, Inc., July 12, 2000, http://www.casewatch.org/fdawarning/
prod/2000/salton.shtml (accessedMar. 15, 2015).
111 GeorgiaC. Ravitz, Counsel for Salton, Inc.,Re:Rejuvenique Facial Toning System, toMr.WilliamF.Defibaugh,
Compliance Offer, Center for Devices and Radiological Health, Aug. 11, 2000, http://media.corporate-
ir.net/media files/nys/sfp/salton rejuv.pdf (accessedMar. 15, 2015).
112 510(k) Summary — Rejuvenique R© Facial Toning System, Aug. 8, 2001, http://www.accessdata.
fda.gov/cdrh docs/pdf/k011935.pdf (accessed Feb. 25, 2015). Note, however, that this pathway was some-
what unusual because a 510(k) is granted when the device is similar in both ‘intended use’ and ‘technological
characteristics’. Here the intended use was cosmetic, not therapeutic.
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TheRejuvenique case is particularly informative, as it exemplifies the typical negotia-
tions between government agency and manufacturer following a warning letter. While
the Rejuvenique manufacturer could have challenged the FDA in court, it chose the
faster and cheaper option of working with the agency. Indeed, practical business con-
siderations may be the best predictor of how a company will engage with the FDA.
Many companies that have a product of unclear regulatory status—especially if they
are investor backed or are looking for funding—will open a dialog with the FDA early
in the development process, so as not to risk later regulatory action. Indeed, it is hard to
imagine that venture capital-backed companies such asThync and Halo Neuroscience
would have been able to raise millions of dollars without a solid regulatory plan. (As
noted in the previous section,Thyncwas in contact with the FDAprior to going tomar-
ket;113 press mentions of Halo Neuroscience have indicated that the company intends
to work with the agency.)114 By contrast, a small-scale tDCS consumer device manu-
facturer without the funds for legal counsel would probably attempt to place its device
outside of the scope of FDA regulation. A manufacturer of this kind who received a
warning letter or notice of violation from the FDA could in theory litigate (assuming
that its product does not have an medical or disease-related intended use according to
all the factors set out in 21 C.F.R. Section 801.4), but in practice it would not likely
be worth the time or money. The section below illustrates what happened when the
state of California—acting on an email from an engineer at the FDA—sent a notice of
violation to a small-scale consumer tDCSmanufacturer.
IV. Regulatory action to date—theCDPHandTDCSDevice Kit, Inc.
Thus far, the only instance of regulatory enforcement against a consumer tDCS de-
vice has come at a state level, from the CDPH, which in May 2013 took action against
a company called TDCS Device Kit, Inc., for violating California’s Sherman Food
Drug, andCosmetic Law.115 According toCalifornia state law,medical devices that are
not federally approved for market in the United States can be considered misbranded
and/or adulterated under the Sherman Law.116 Furthermore, the Sherman Law re-
quires anyonemanufacturing amedical device inCalifornia to obtain a license from the
CDPH.117
According to the CDPH report, the investigation of TDCS Device Kit was initi-
ated following receipt of an email and five-page analysis from a biomedical engineer
at the FDA’s Center for Devices and Radiological Health.118 The company, which
113 Interview withWilliam (Jamie) Tyler, co-founder and chief scientific officer (CSO) ofThync, Feb. 12, 2015.
114 Ben Popper,TheHaloNeuroscienceHeadbandWants toMake You Smarter by Shocking Your Brain,THEVERGE,
April 30, 2014, http://www.theverge.com/2014/4/30/5668086/halo-neuroscience-brain-stimulation-
funding-andreessen (accessed Feb. 25, 2015); John Biggs, Halo, the Brain-Improving Wearable, Raises $1.5
Million, TECH CRUNCH, May 1, 2014, http://techcrunch.com/2014/05/01/halo-the-brain-improving-
wearable-raises-1-5-million/ (accessed Feb. 25, 2015).
115 State ofCaliforniaDepartment of PublicHealth, Food andDrugBranch,MedicalDevice SafetyUnit,Medical
Device Investigative Report, TDCS Device Kit, Inc., inspection date May 7, 2013.
116 Cal. HSC. Code § 109875 et seq. See also infra 143 and 144 and related text for a discussion of the overlap
between federal and state medical device laws.
117 Cal. HSC. Code § 111615.
118 The engineer was in the Office of Device Evaluation/Division of Neurological and Physical Medicine De-
vices/Physical Medicine and Neurotherapeutic Devices Branch (CDRH/ODE/DNPMD/PNDB); supra
note 115.
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was based in California, had been selling a ‘Home TDCS Device Kit’ via its website
(www.tdcsdevicekit.com). The FDA engineer had concluded that the ‘Home TDCS
Device Kit’ was a Class III medical device and would require 510(k) clearance to be
legallymarketed in theUSA, as the company’s website implied that the device could be
used to treat a variety of disorders. Although the company never explicitly claimed that
its own device had medical benefits, its website did contain several paragraphs about
tDCS, with sentences such as: ‘Clinical therapy using TDCSmay be the most promis-
ing application of this technique. There have been therapeutic effects shown in clini-
cal trials involving Parkinson’s disease, tinnitus, fibromyalgia, and post-stroke motor
deficits’.
InMay 2013, an investigator from theCDPHcontacted the president of TDCSDe-
viceKit, RichardO’Rourke, who believed that his product did not requireCDPHclear-
ance, since the product was a kit that was assembled by the user. A few days later, the
same investigator met O’Rourke and inspected the manufacturing facility; the com-
pany was issued a notice of violation that day for non-compliance with California’s
Sherman Food, Drug and Cosmetic Law for manufacturing medical devices without
a license from the CDPH.119 Two weeks later, the CDPH issued TDCS Device Kit
a second notice of violation, this time with 11 items related to ‘selling and deliver-
ing misbranded, adulterated, and unapproved medical devices’. According to the no-
tice of violation, the device was unapproved by the FDA; it was adulterated in that it
did not comply with good manufacturing practices and performance standards; and it
was misbranded in that the manufacturing establishment was not licensed by the FDA
or the CDPH, and the label failed to bear adequate warnings, directions, and other
information.120
The company subsequently stopped selling the devices, and a sentencewas added to
its website, noting that the kits were ‘unavailable at this time’. O’Rourke, however, was
reluctant to issue a recall, and evidently did not take action to meet with the FDA or
medical device regulatory counsel to negotiate a plan to secure approval for the device.
Therefore, the CDPH moved forward, issuing a press release on June 28, 2103, titled
‘CDPHWarns Consumers Not to Use TDCS Home Device Kit’.121 The next month,
TDCS Device Kit sent out a recall email to over 200 customers. The investigation was
officially closed inOctober 2013, following aCDPHdetermination that thefirm’s recall
efforts were adequate.122
There are several contextual points of interest in this case. First, it remains an open
question why the FDA engineer conducted his or her own analysis, yet forwarded the
issue to the CDPH. One possibility is that the FDA engineer did not have evidence of
the product being sold across state lines; the FDA’s jurisdiction lies only in interstate
commerce, not in intrastate commerce.123 Another possibility is that it was simpler to
hand the case off to the state and not engender complex federal regulatory processes.
119 Supra note 117.
120 Supra note 115.
121 California Department of Public Health, CDPH Warns Consumers Not to Use TDCS Home Device Kit, June
28, 2013, http://www.cdph.ca.gov/Pages/NR13-029.aspx (accessed Feb. 1, 2015).
122 State ofCaliforniaDepartment of PublicHealth, Food andDrugBranch,MedicalDevice SafetyUnit,Medical
Device Investigative Report, TDCS Device Kit, Inc., inspection date Oct. 7, 2013.
123 Infra note 144.
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In response to a query regarding the frequency of FDA referrals for medical device in-
vestigations, the CDPH noted that such referrals occur ‘occasionally’.124
Second, all items in the 11-item notice of violation referred to the device as a ‘pre-
scription medical device’ (emphasis added). The fifth item on the notice of violation
was based entirely on this characterization, stating that the device was misbranded be-
cause the label failed to bear the statement ‘Caution: federal law prohibits dispensing
without a prescription. . . ’ or similar language. However, there is no clinical use of tDCS
that is FDA approved, either for prescription or over-the-counter use. When queried
about the use of the term, the CDPH noted that when ‘additional information was ob-
tained, it was determined the product was an unapproved new medical device as op-
posed to a prescription medical device’.125 Indeed, the second, shorter CDPH report
does not mention the word ‘prescription’, but it also does not make note of the initial
error.
Third, even though TDCS Device Kit never made a specific disease or struc-
ture/function claim for its product, the report states that treatment claims were ‘im-
plied’ by the website.Thus, if statements about the clinical effects of tDCS appear on a
website that sells a consumer tDCS device, representatives from the FDA and the state
of California have inferred that the product is a medical device. Furthermore, design-
ing and marketing a consumer tDCS device as a ‘kit’ made no meaningful difference.
Thus, severalmanufacturers that currently sell consumer tDCS devicesmay be liable to
receive notices of violation (at the state or federal level) for unapproved, adulterated,
or misbranded medical devices. As noted in Part II, several manufacturers link to, or
mention, research regarding the therapeutic effects of tDCS.
Fourth, according to the CDPH report, the FDA engineer’s five-page analysis con-
cluded that the device was a Class III device that would require a 510(k) clearance
before marketing. This implies that the FDA engineer had characterized the device as
substantially equivalent to an existing pre-amendment Class III device, which as men-
tioned in Part II, is a device that poses the highest risk of injury and illness. The ex-
isting Class III device most similar to tDCS is a CES device, which according to the
FDA’s definition, ‘applies electrical current to a patient’s head to treat insomnia, de-
pression, or anxiety’.126 The main difference between the two is that while tDCS uses
direct current, CES uses alternating current.127 The assumption of substantial equiv-
alence to CES would explain the CDPH report’s (incorrect) observation that tDCS
‘is typically used to treat depression and other mood disorders’. It would also explain
the use of the term ‘prescription’ in the CDPH’s violation notice, as CES is currently a
prescription-only device.
124 E-mail from Ronald Owens, Office of Public Affairs, California Department of Health, to AnnaWexler (Feb.
13, 2015), on file with author.
125 E-mail from Ronald Owens, Office of Public Affairs, California Department of Health, to AnnaWexler (Feb.
2, 2015), on file with author.
126 21 C.F.R. § 882.5800 (2015).
127 Although the FDA’s definition of CES is broad, the agency has elsewhere described the specific charateristics
of CES and has distinguished it from tDCS. See eg, Section 1.2 in US Food and Drug Administration,
FDA Executive Summary: Prepared for the February 10, 2012 meeting of the Neurologic Devices Panel,
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/
MedicalDevicesAdvisoryCommittee/NeurologicalDevicesPanel/UCM290787.pdf (accessed Sep. 22,
2015).
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The comparison of tDCS to CES is especially interesting in light of the ongoing bat-
tles about whether CES should be categorized as a Class II or Class III device. As men-
tioned earlier, the vast majority of non-invasive electrical stimulation devices for med-
ical purposes are categorized as Class II devices, and CES manufacturers have long at-
tempted to have the CES device reclassified from aClass III to Class II. In recent years,
however, the FDA has tried unsuccessfully, and against heavy resistance, to increase the
burden on CES manufacturers.128 In June 2014, in response to a flood of public com-
ments, the FDA stated that it planned to reclassify the device as Class II, although it
has yet to follow through with this reclassification.129 It is likely that the particular CES
troubles are a consequence of being grandfathered in under the 1976 Medical Device
Amendments and automatically categorized as a Class III device; CES was therefore
never required to submit a PMAdemonstrating safety and efficacy.The lack of PMA for
CES also explains the FDA engineer’s surprising determination that the ‘Home TDCS
Device Kit’ was substantially equivalent to an existing Class III device and would re-
quire 510(k) clearance, as most new Class III devices cannot be cleared via the 510(k)
process. The engineer likely had CES in mind, because the only instance where a new
Class III device can be cleared via the 510(k) process is if it can demonstrate substantial
equivalence to a ‘preamendment’ device that was automatically classified as Class III,
such as CES.130
In sum, the CDPH case shows that contrary to common perception, the FDA has
been involved in the regulation of consumer tDCS devices; however, it should be
emphasized that the FDA engineer’s email and analysis does not represent the formal
position of the FDA.131 Though there was initial uncertainty on the part of the CDPH
regarding the status of consumer tDCS devices, state and federal regulators still con-
sidered the product to be a medical device based on manufacturer’s statements about
the therapeutic effects of tDCS. Importantly, the use of the term ‘kit’ did not offer any
protection. Finally, the only documented case to date of the FDA’s involvement in
tDCS indicates that at least one engineer in its offices has viewed tDCS formedical pur-
poses as a Class III device. While this will likely be surprising for researchers who have
128 In 2011, the FDA issued a proposed rule to require the filing of a PMA (or a notice of completion of a product
development protocol, PDP) for CES devices. In response, three petitions were filed by CESmanufacturers,
requesting reclassificationofCESdevices intoClass II.Thepetitionswere referred to a 2012NeurologicalDe-
vice Panel, which agreed that the devices should require PMAs and remain in Class III. In April 2013 (around
the time the FDA emailed theCDPH), the FDA issued an order to require additional pre-market approval for
CESdevices. See Background section,USFood andDrugAdministration,NeurologicalDevices;Withdrawal
of Proposed Effective Date of Requirement for Premarket Approval for Cranial Electrotherapy Stimulator Devices,
79 Fed. Reg. 33,712 (June 12, 2014), to be codified at 21 C.F.R. 882.
129 Id.
130 See infra note 63.
131 Under 21 C.F.R. 10.85(k), a statement by an FDA employee represents only the best personal judg-
ment of that individual and ‘does not necessarily represent the formal position of FDA, and does
not bind or otherwise obligate or commit the agency to the views expressed’. 21 C.F.R. 10.85(k),
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=10.85 (accessed Jan. 25,
2015).
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assumed that tDCS for medical use would be a Class II device, the report should be
taken with a grain of salt, as the FDA engineer’s analysis is not representative of the
agency’s formal position. Indeed, another device similar to tDCS—one that provides
electrical stimulation to the head for headache treatment—was recently classified by
the FDA as a Class II device.132
V. Safety and advertising regulations for consumer products
If the FDA does not recognize consumer tDCS devices as medical devices (or opts not
to enforce existing regulations), such products would still be subject to a multitude of
consumer product safety and advertising laws. For example, the Federal Trade Com-
mission (FTC) has the authority to take relevant administrative action for ‘unfair or
deceptive’ business practices.133 The FTC interprets the term ‘deceptive’ broadly—to
include ‘sales of hazardous. . . products. . .without adequate disclosures’—and therefore
issues related to the sale of consumer tDCSproducts could fall under its scope.134 While
the FTC regulates the advertising of consumer products as well as over-the-counter
drugs and medical devices, the FDA maintains regulatory authority over the advertis-
ing of restricted (ie prescription) drugs and medical devices, and for the labeling of
all products under its jurisdiction.135 Thus, if the FDA classifies consumer tDCS prod-
ucts as unrestrictedmedical devices, oversight of their advertising would fall under the
FTC and labeling under the FDA; if such devices are considered consumer products,
oversight of both advertising and labeling would fall under the broad brush of the FTC.
Two recent FDA guidances—the wellness device draft guidance mentioned in Part
II and a 2015 guidance regarding health-related mobile applications—seem to shift a
regulatory burden to the FTC by placing a large class of wellness products outside the
scope of FDA regulation.136 Indeed, the FTC recently filed a complaint against a com-
pany marketing a computer game that claimed to improve cognition in children.137 It
132 US Food and Drug Administration,Medical Devices; Neurological Devices; Classification of the Transcutaneous
Electrical Nerve Stimulator to Treat Headache, 79 Fed. Reg. 37,946 (July 3, 2014) to be codified at 21 C.F.R.
882,https://www.federalregister.gov/articles/2014/07/03/2014-15625/medical-devices-neurological-
devices-classification-of-the-transcutaneous-electrical-nerve (accessed Feb. 22, 2015).
133 15 U.S.C. § 45(a)(1) (2012).
134 Federal Trade Commission, FTC Policy Statement on Deception, http://www.ftc.gov/public-statements/
1983/10/ftc-policy-statement-deception (accessed Jan. 25, 2015).
135 Although the FDA and FTC have overlapping jurisdiction, since 1954 they have operated under a
Memorandum of Understanding. However, it should be noted that the Memorandum is only an in-
formal division of authority. Working Agreement Between Federal Trade Commission and Food
and Drug Administration, 36 Fed. Reg. 18,539 (Sept. 16, 1971), http://www.fda.gov/AboutFDA/
PartnershipsCollaborations/MemorandaofUnderstandingMOUs/DomesticMOUs/ucm115791.htm (ac-
cessed Jan. 20, 2015). See also discussion in James Serafino,Developing Standards for Health Claims-The FDA
and the FTC, 47 FOOD &DRUG L.J. 335, 335–337 (1992).
136 US Food and Drug Administration, Mobile Medical Applications: Guidance for Industry and Food and Drug
Administration Staff (Feb. 9, 2015), http://www.fda.gov/downloads/MedicalDevices/. . ./UCM263366.pdf
(accessed Feb. 22, 2015).
137 Federal Trade Commission, Press Release, Makers of Jungle Rangers Computer Game for Kids Set-
tle FTC Charges that They Deceived Consumers with Baseless ‘Brain Training’ Claims, Jan. 20, 2015,
http://www.ftc.gov/news-events/press-releases/2015/01/makers-jungle-rangers-computer-game-kids-
settle-ftc-charges-they (accessed Feb. 26, 2015).
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also has pursued action against variousmobilemedical health apps in recent years, such
as ones that have claimed to treat acne and diagnose melanoma.138
With regard to safety, the CPSC is tasked with protecting the public from ‘unrea-
sonable risks of injury associated with consumer products’,139 and regulates products
such as table saws, cribs, and carbon monoxide detectors. The CPSC has the author-
ity to ban products, develop safety standards, and facilitate product recalls. All med-
ical devices (and other products regulated by the FDA) fall outside the scope of the
CPSC.140 It should be noted, however, that as a matter of practice, some authori-
ties may be reluctant to take enforcement action over a product that may fall un-
der the primary jurisdiction of another agency. For example, if a product has the ap-
pearance of a medical device, an agency such as the CPSC may be hesitant to assert
jurisdiction.
Another federal agency, the FCC, regulates the radio frequency output of various
wireless technology devices, ensuring that they meet certain standards. While most
tDCS devices from small-scale vendors do not incorporate wireless technology, both
the Foc.us and the Thync devices have FCC certification, as they can be controlled
wirelessly from a smartphone.141 The FCC and the FDA in some cases have over-
lapping jurisdiction, as they both regulate radiation-emitting products. For example,
the FCC certifies cell phones and ensures that they meet certain radio frequency
standards, whereas the FDA is responsible for potential cell phone-related health
issues.142
In addition to federal regulations, individual states also have health, safety, andmed-
ical device laws. According to section 521 of the FD&C Act, the FDA’s medical de-
vice regulations preempt (ie supersede) state laws.143 Though the overlap between fed-
eral and state regulations is complex, in general, a state law cannot interfere with FDA
regulations (eg it cannot set lesser criteria for what constitutes amedical device). How-
ever, in some cases a state can apply additional rules or more stringent requirements.
For example, the first notice of violation issued to TDCS Device Kit was related to a
state requirement (lack of licensing from the CDPH), not a federal one. Furthermore,
138 Federal Trade Commission, Press Release, ‘Acne Cure’ Mobile App Marketers Will Drop Baseless
Claims Under FTC Settlements, Sept. 8, 2011, https://www.ftc.gov/news-events/press-releases/2011/
09/acne-cure-mobile-app-marketers-will-drop-baseless-claims-under (accessed Jan. 8, 2015); and Federal
Trade Commission, Press Release, FTC Cracks Down on Marketers of ‘Melanoma Detection’ Apps, Feb. 23,
2015, https://www.ftc.gov/news-events/press-releases/2015/02/ftc-cracks-down-marketers-melanoma-
detection-apps (accessedMar. 1, 2015).
139 Consumer Product Safety Act (Codified at 15 U.S.C. §§ 2051−2089).
140 US Consumer Product Safety Commission, Products Under the Jurisdiction of Other Federal Agencies,
http://www.cpsc.gov/en/Regulations-Laws–Standards/Products-Outside-CPSCs-Jurisdiction/ (accessed
Jan. 25, 2015).
141 The application for FCC certification for the Foc.us devices (submitted by European Engineers Lim-
ited, FCC ID: 2AAH6DLIG1) and for the Thync device (FCC ID: 2AELZ-1000) are publicly viewable
via an ‘Equipment Authorization Search’ on the FCC website: https://apps.fcc.gov/oetcf/eas/reports/
GenericSearch.cfm (accessed Jan. 8, 2015).
142 USFood andDrugAdministration,Radiation-Emitting Products - Cell Phones, http://www.fda.gov/radiation-
emittingproducts/radiationemittingproductsandprocedures/homebusinessandentertainment/cellphones/
default.htm (accessed Jan. 25, 2015).
143 Section 521(a) of FD&C act, as codified in 21 C.F.R. § 808. For discussion, see Hutt et al., supra note 51 at
1280, 1282.
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the FDA has jurisdiction only over interstate commerce, not intrastate commerce.144
Currently, all US-based consumer tDCS device manufacturers are selling their prod-
ucts on an interstate level, but if every part of a device were to be manufactured and
sold entirely within a single state—which, of course, is highly unlikely—the product
would fall under state, and not FDA, jurisdiction. States also have their own consumer
protection laws (often for unfair or deceptive business practices) that would be appli-
cable in the realm of consumer tDCS.
With regard to the importation of foreign tDCS devices into theUSA (such as those
from theHongKong-based companies TCTResearch Limited and PriorMind, both of
whichmake explicit medical claims), the FDA imposes identical requirements on both
foreign and domestic devices.145 The FDA works with the Department of Homeland
Security to inspect food, drugs, cosmetics, and medical devices, and the government
has broad powers to detain or seize imports.146 However, the FDA recognizes that it is
not practical to inspect every item imported into theUSA, and the agency has therefore
been permissivewith small quantities of drugs or devices imported for personal use. Ac-
cording to theFDA’sRegulatoryProceduresManual, the agency exercises enforcement
discretion even for items that are in clear violation of FDA regulations. However, the
manual notes that although the FDA ‘may use discretion to allow admission of certain
violative items, this should not be interpreted as a license to individuals to bring in such
shipments’.147 The FDA is more likely to take enforcement action when the product
presents a health risk, if it is being actively promoted to US customers, or if it is being
shipped repeatedly and/or in large quantities.
Finally, the Better Business Bureau (BBB), a non-profit non-governmental organi-
zation, plays amajor role inwhat it is referred to as industry ‘self-regulation’.148TheBBB
interfaces between companies and consumers to settle complaints outside of court; it
has already helpedone consumerwith a complaint about theFoc.us device.149TheBBB
also has aNationalAdvertisingDivision,whichmonitors companies’ advertising claims
and attempts to resolve matters through settlements.150 Thus, even if consumer tDCS
devices are not regulated as medical devices by the FDA, they would still be subject to
numerous federal and state consumer product laws.
144 Section 301 of the FD&CAct.
145 Section 801(a) of the FD&CAct.
146 See Hutt et al., supra note 51 at 1450 for discussion of different outcomes for seizure as compared to refusal
of admission.
147 US Food and Drug Administration, Regulatory Procedures Manual, 9–2, Coverage of Personal Impor-
tations, http://www.fda.gov/ICECI/ComplianceManuals/RegulatoryProceduresManual/ucm179266.htm
(accessed Jan. 10, 2015).
148 Council ofBetterBusinessBureaus,MissionandVision, http://www.bbb.org/council/about/vision-mission-
and-values/ (accessed Jan. 15, 2015); FTC Commissioner Maureen K. Ohlhausen has defined self-
regulation as a ‘broad concept that includes any attempt by an industry to moderate its conduct
with the intent of improving marketplace behavior for the ultimate benefit of consumers’. Maureen K.
Ohlhausen, Remarks at the BBB Self-Regulation Conference, June 24, 2014, at 2, http://www.ftc.gov/system/
files/documents/public statements/410391/140624bbbself-regulation.pdf (accessed Jan.10, 2015).
149 BBB Business Review, European Engineers Limited (see ‘Complaint Resolution Log’) http://www.bbb.
org/greater-san-francisco/business-reviews/home-electronics/european-engineers-limited-in-redwood-
city-ca-459140/complaints (accessed Jan. 25, 2015).
150 National Advertising Division, http://www.bbb.org/council/the-national-partner-program/national-
advertising-review-services/national-advertising-division/ (accessed Jan. 25, 2015).
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CONCLUSION
In sum, this paper has offered an in-depth, fact-based perspective on the regulation of
consumer tDCS devices in the United States. Rather than a ‘regulatory gap’, there are
multiple, distinct pathways by which consumer tDCS devices can be regulated in the
United States. An examination of the existing consumer device market illustrated the
complex array of various tDCS devices and the shift fromDIY devices to DTC ones. A
review of the statutory language of the FD&CAct as well as related judicial and agency
interpretations demonstrated the importanceof considering theprecise languageof the
law (and the intended use claimsmade for each consumer tDCS device) as well as how
the courts have construed the FDA’s authority. Although it is unclear whether the FDA
or states will attempt to assert jurisdiction over small-scale consumer tDCS manufac-
turers, if regulatory action is initiated, such small-scale manufacturers may be able to
challenge the FDA in limited circumstances,151 though in practice this is unlikely to be
a successful or worthwhile endeavor. In addition, an analysis of the state regulatory ac-
tion taken against TDCSDevice Kit revealed one FDA engineer’s interpretation that a
consumer tDCSproductwas aClass III device; it alsoprovidedan indicationof the level
of scrutiny that states and federal bodies might adopt in determining what constitutes
an ‘implied’ therapeutic use claim. Finally, I have shown that if the FDA does not regu-
late consumer tDCS products as medical devices, such products would still be subject
to a multitude of consumer safety and advertising regulations, although enforcement
may not be vigorous.
Taken together, existing authorities provide diverse regulatory options. For exam-
ple, products such as the Foc.us and tDCS device kits could be regulated as consumer
devices, and thereforewouldbe subject to the consumer safety andadvertising lawsout-
lined in the previous section. Foreign device manufacturers who ship consumer tDCS
devices to the USA (such as TCT Research Limited and PriorMind) might not en-
counter regulatory issues if they ship in limited quantities to individuals for personal
use. Companies with greater resources, such as Thync and Halo Neuroscience, may
be more likely to work with the FDA; as mentioned above, according toThync’s press
release, the FDA exempted the company from obtaining approval or clearance for its
device.
Separate from consumer tDCS devices, medical and investigational devices have
their own regulatory pathways. Neuroconn could continue to provide its tDCS de-
vice to clinicians and researchers for investigational purposes only, under the FDA’s
investigational device exemption. Scientists could continue to repurpose iontophore-
sis devices for use in research studies as long as such devices are deemed to be non-
significant risk devices by their local Institutional Review Board. With regard to treat-
ment, psychiatrists and other medical professionals could continue to repurpose ion-
tophoresis devices for ‘off-label’ use for either cognitive enhancement or treatment;
such a practice is legal in the United States.152 In the future, a company could demon-
strate the safety and efficacy of its device for a specific clinical use (eg depression) and
151 Since 21 C.F.R. Section 801.4 allows the FDA to consider a broad range of factors in determining intended
use, I use ‘limited circumstances’ here to refer to a situation wherein a disease claim or medical-related struc-
ture/function claim could not be construed based on all the factors set out in that section.
152 See supra note 96.
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see it approved or cleared as a prescription-only medical device. Thus, while all of the
above-mentioned examples involve some form of tDCS, each is subject to different
forms of oversight.
Given the multitude of regulation covering various forms of tDCS devices, it is
unclear how additional regulation might fit into the picture. Indeed, as I mentioned
at the outset, many scholars have conflated the lack of enforcement with the lack
of regulation. Furthermore, much of the existing literature has neglected to con-
sider current legal frameworks and factors such as the practical feasibility of imple-
mentation (ie the procedures, costs, and length of time required to modify regula-
tion), the precise targets of regulation (exactly which devices additional regulation
would affect, and how), and possible social implications (such as the possibility that
home users might go further ‘underground’ in response to a regulatory push). In-
deed, modifying a regulatory framework to questionably encompass a small sliver of
devices that have yet to cause any serious adverse effects seems both impractical and
unrealistic.
Rather than focusing on the enforcement of existing regulation153—which would
not affect the use of home-built devices, theThync device and iontophoresis devices—
a more productive method might be to begin with a review of existing devices and the
populations who use them, outlining the relevant issues of concern surrounding con-
sumer non-invasive brain stimulation. While there has been a large body of literature
on the ethics of cognitive enhancement drugs (eg inequalitywith regard to distribution,
compelled use), the bulk of the conversation surrounding consumer tDCS devices has
focused on issues of safety and risk. However, further clarification is necessary when
using these terms, as even a device that complies with regulatory standards may not be
‘safe’ under certain usage practices (eg long-term use of the Thync device); whereas
a device that does not meet technical output standards may be safe when used in a
specific manner (eg a ‘DIYer’ using a home-built device). In other words, who is using
the device is just as important as what device they are using. Furthermore, it is crucial
to differentiate between short-term safety issues (eg side effects such as skin irritation
and headaches) and long-term unknowns (eg the possibility of deleterious cognitive
effects).
Importantly, the review could focus on establishing guidelines that address usage
practices, rather than devices themselves. Such guidelines, which would be along the
lines of the engagement approach that has been previously suggested in the litera-
ture,154 could target home users, the general public, and physicians who currently ad-
minister tDCS for off-label use. Guidelines could reflect best usage practices, as well
as current unknowns in the literature, and leave it to the users to make informed de-
cisions. Such an approach could be quickly implemented, flexible, and would reach
a global audience, rather than being limited to a specific country. Indeed, qualitative
153 In most cases, a federal or state agency cannot be compelled to enforce existing regulation. However, com-
plaints may be filed with the various regulatory authorities.
154 See Fitz & Reiner, supra note 14, and Nicholas S. Fitz & Peter B. Reiner, Buttressing Regulation of Cognitive
Enhancement Devices with Principles of Harm Reduction, 1 J. L. BIOSCI. 322 (2014).
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studies have shown that tDCS home users look to the scientific community for guid-
ance155 and would be open to guidelines from researchers.156
Though an engagement approach to the regulatory issues surrounding DIY tDCS
was first proposed two years ago, as of yet, no initiative has come to fruition. Indeed,
there are a number of practical barriers that should be acknowledged. First, as home
users are perceived as ‘fringe’ or ‘unorthodox’ by much of the scientific community,
there is likely a stigma attached to engagingwith themdirectly. Second, given that tDCS
is still verymuch in research and investigational stages, most scientists are probably un-
willing to make proclamations about what is safe and what is not, and would likely not
want to take steps thatmaybeperceived as encouraging unsupervised use.Third, guide-
lines could lead to liability issues (eg if a home user injured himself despite following
the guidelines). Fourth, given the lack of consensuswithin the tDCSfield itself (egwith
regard to optimal dosage andpotential long-termdeleterious effects), itmay be difficult
for researchers to agree on a single set of guidelines.
Given these obstacles, it may be beneficial for such guidelines to be developed un-
der the umbrella of a reputable third party, such as the National Academy of Medicine
(formerly known as the Institute of Medicine) or a neuroethics committee. A third-
party might alleviate some of the stigma of interacting directly with the home users,
and protections could be put into place to shield individual researchers from liability
issues. Rather than reflecting a single consensus, guidelines could summarize the lat-
est research regarding the short- and long-term issues regarding tDCS, with a focus on
minimizing side effects and encouraging safe usage practices. Importantly, the com-
mittee could be an avenue not just for one-way communication from researchers to
home users and the general public, but a venue for representatives of various groups
to interact. Qualitative and quantitative work should continue to track tDCS home
use and its potential uptake by the general public, in order to provide ongoing in-
formation regarding the use of non-invasive brain stimulation outside of academic
settings.
Looking ahead, it is clear that electrical brain stimulationwill soon become available
to a larger audience than it ever has before. IfThync’s initial results are borne out—and
its device does have the same effect as a glass of wine or a cup of coffee—then the tech-
nology could be profoundly transformative in ways that we cannot yet grasp. Rather
than adopting an alarmist approach to the new reality of consumer brain stimulation,
we must navigate this unfamiliar terrain with practical, grounded assessments of social
and regulatory issues. Establishing a forum for the continued interaction among man-
ufacturers, home users, and regulators would represent an important first step in this
direction.
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